Document:

Development, Commercialization and Licensing Agreement

 Exhibit 10.11 
 DEVELOPMENT, COMMERCIALIZATION AND LICENSING AGREEMENT 
 BETWEEN 
 ARCA DISCOVERY, INC. 
 AND 
 LABORATORY CORPORATION OF AMERICA HOLDINGS

 DATED FEBRUARY 1, 2007 

 DEVELOPMENT, COMMERCIALIZATION AND LICENSING AGREEMENT 
 This Development, Commercialization and Licensing Agreement (this “Agreement”) is made and entered into as of
February 1, 2007 (the “Effective Date”) between ARCA Discovery, Inc., a Delaware corporation (hereinafter “ARCA”), and Laboratory Corporation of America Holdings, a Delaware corporation (hereinafter
“LabCorp”). 
 INTRODUCTION 
 A. ARCA holds certain proprietary rights to Bucindolol and to the Diagnostic Tests (as such terms are hereinafter defined). 

 B. ARCA intends to seek FDA approval for the use of Bucindolol in the treatment of heart failure and other indications
and for labeling for Bucindolol that recommends or requires use of the Diagnostic Tests with Bucindolol. 
 C.
LabCorp possesses development and commercialization capabilities with respect to laboratory testing services and desires to collaborate with ARCA to develop, make, market and sell the Diagnostic Tests in the United States in connection with the
administration of Bucindolol (the “Services”). 
 D. LabCorp desires to obtain from ARCA, and
ARCA desires to grant to LabCorp, an exclusive license to practice the ARCA Patent and use the Trademark in connection therewith, and an exclusive sublicense to ARCA’s rights in the Diagnostic Tests for the development, marketing, manufacture
and sale of the Diagnostic Tests on the terms and conditions set forth this Agreement. 
 NOW, THEREFORE, in
consideration of the foregoing premises and the mutual covenants contained herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 For purposes of this Agreement, the terms defined in this Article I shall have the following
meanings, whether used in their singular or plural forms. Use of the singular shall include the plural and vice versa, unless the context requires otherwise: 
 1.1 “Act” shall mean the U.S. Food, Drug and Cosmetic Act, as amended, 21 U.S.C. 301 et. seq., and the regulations promulgated thereunder. 
 1.2 “Affiliate” shall mean, with respect to any Party, any corporation or other entity that, directly or indirectly, by
itself or through one or more intermediaries, controls, or is controlled by, or is under common control with such party, or has the power to direct or cause the direction of the management and policies of a Party, whether through the ownership of
voting securities, by contract or otherwise. Control will be presumed if one Party owns, either of record or beneficially, more than 50% of the voting stock of any other Party, at the applicable time during the term of this Agreement. 
  

 Development, Commercialization and Licensing Agreement-Confidential-Page 1 

 1.3 “ARCA Inventions” shall have the meaning set forth in
Section 8.1 of this Agreement. 
 1.4 “ARCA Know-How” shall mean all Know-How owned or Controlled
by ARCA as of the Effective Date. 
 1.5 “ARCA Patent” means U.S. Provisional Application Serial
No. 60/609,689 filed September 14, 2004; U.S. Provisional Application Serial No. 60/610,706 filed September 17, 2004; International Patent Application titled “Method for treatment with bucindolol based on genetic
targeting,” WO 20061031955 A2, filed September 14, 2005; U.S. Application Serial No. 11/226,908 filed September 14, 2005; any letters patent issued from any of the foregoing, and all continuations, continuations-in-part,
divisions, and renewals thereof, all patents which may be granted thereon, and all or reissues, reexaminations, extensions, patents of additions and patents of importation thereof. 
 1.6 “ARCA Technology” shall mean the ARCA Patent and all ARCA Know-How related thereto. 
 1.7 “Bankruptcy Event” shall mean the Party in question becomes insolvent, or voluntary or involuntary proceedings by or
against such Party are instituted in bankruptcy or under any insolvency law, or a receiver or custodian is appointed for such, or proceedings are instituted by or against such Party for corporate reorganization or the dissolution of such Party,
which proceedings, if involuntary, shall not have been dismissed within sixty (60) days after the date of filing, or such Party makes an assignment for the benefit of its creditors, or substantially all of the assets of such Party are seized or
attached and not released within sixty (60) days thereafter. 
 1.8 “Bucindolol” shall
mean the beta-adrenergic-receptor antagonist having the chemical formula bucindolol HCL (oral)2-{2-hydroxy-3 { {2-(3-indolyl)-1, 1-dimethylethyl}amino}propxy}-benzonit, and its racemates, isomers, prodrugs, active metabolites, analogs and
any pharmaceutically acceptable salt or complex thereof. 
 1.9 “CardioDx” shall mean CardioDx, Inc., a
Delaware corporation. 
 1.10 “CardioDx Agreement” shall mean that certain Diagnostic Collaboration and Option
Agreement dated as of June 23, 2006 between ARCA and CardioDx, as the same may be amended from time to time. 
 1.11
“Change of Control” means an event as a result of which the holders of the outstanding voting securities of a Party or the Persons with the power to direct or cause the direction of the management and policies of a Party as of the
Effective Date of this Agreement cease to own a majority of the outstanding voting securities of such Parry or the power to direct or cause the direction of the management and policies of such Party. 
 1.12 “Combination Product” shall have the meaning set forth at 21 C.F.R.§ 3.2(e). 
 1.13 “Commercial Plan” shall have the meaning set forth in Section 5.2 of this Agreement. 
  

 Development, Commercialization and Licensing Agreement-Confidential-Page 2 

 1.14 “Commercial Platform” shall mean a commercially-feasible and
analytically-valid laboratory method of performing the Diagnostic Tests. The Commercial Platform may be made available initially in the form of a Homebrew Assay, and later as an IVD Product and an IVD Kit. 
 1.15 “Commercialization Plans” shall mean, collectively, the Commercial Plan, the Marketing and Sales Plan, and the
Reimbursement Plan. 
 1.16 “Controlled” shall mean the legal authority or right of a Party hereto to grant a
license or sublicense of intellectual property rights to another Party hereto, or to otherwise disclose proprietary or trade secret information to such other Party, without breaching the terms of any agreement with a Third Party, infringing upon the
intellectual property rights of a Third Party, or misappropriating the proprietary or trade secret information of a Third Party. 
 1.17 “Diagnostic Tests” shall mean the performance of an assay to detect the presence of two polymorphisms identified in the ARCA Patent in each of the Alpha 2C and Beta-1 cardiac adrenergic receptors.

 1.18 “Diagnostics Committee” shall have the meaning set forth in Section 3.2 of this Agreement.

 1.19 “Dollars” and “$” shall mean United States dollars. 
 1.20 “Drug Product” shall mean any pharmaceutical preparation in finished dosage form containing Bucindolol for
administration to human patients. 
 1.21 “Effective Date” shall mean the effective date of this Agreement as
set forth on the first page hereof. 
 1.22 “FDA” shall mean the United States Food and Drug Administration or
any successor agency thereto. 
 1.23 “Field” shall mean the performance, administration or use of the
Diagnostic Tests in connection with the prescription, administration or use of Bucindolol, including as a Combination Product, in the treatment of heart failure or cardiovascular disease in humans. 
 1.24 “GMP” shall mean the current Good Manufacturing Practice regulations and the Quality System Regulations promulgated by
the FDA, including 21 C.F.R. Parts 210, 211, and 820 et seq., as such regulations may be amended from time to time, and such equivalent regulations or standards of countries outside the United States as may be applicable to activities conducted
hereunder. 
 1.25 “Governmental Authority” means any applicable federal, state, local or other governmental
body with jurisdiction over the applicable subject matter. 
 1.26 “Homebrew Assay” shall mean an in-house
laboratory test developed pursuant to the Clinical Laboratory Improvement Amendments of 1988. 
  

 Development, Commercialization and Licensing Agreement-Confidential-Page 3 

 1.27 “Indemnitee” shall have the meaning set forth in Section 11.3
of this Agreement. 
 1.28 “Indemnitor” shall have the meaning set forth in Section 11.3 of
this Agreement. 
 1.29 “Information” shall mean any and all information and data, including scientific,
pre-clinical, clinical, regulatory, manufacturing, marketing, financial, and commercial information. 
 1.30 “IVD
Product” shall mean an in vitro diagnostic medical device, as defined in regulation at 21 C.F.R. § 809.3(a), that is developed for the Commercial Platform and that requires Regulatory Approval. 
 1.31 “IVD Kit” shall mean an IVD Product that is developed in a kit form and that requires Regulatory Approval so that the
Commercial Platform may be performed in a de-centralized fashion by LabCorp or by Third Parties. 
 1.32 “Joint
Inventions” shall have the meaning set forth in Section 8.1 of this Agreement. 
 1.33
“Know-How” shall mean all proprietary material and information including data, technical information, know-how, experience, inventions, discoveries, trade secrets, compositions of matter and methods, that relate to the development,
utilization, manufacture or use of the Diagnostic Tests or Drug Product, including but not limited to processes, techniques, methods, products, materials and compositions. 
 1.34 “LabCorp Inventions” shall have the meaning set forth in Section 8.1 of this Agreement. 
 1.35 “Loss” shall have the meaning set forth in Section 11.1 of this Agreement. 
 1.36 “Marketing and Sales Plan” shall have the meaning set forth in Section 5.3 of this Agreement. 

1.37 “Net Sales” [    *    ]. 
 1.38 “New Inventions” shall have the meaning set forth in Section 8.1 of this Agreement. 
 1.39 “Party” shall mean ARCA or LabCorp, and “Parties” shall mean ARCA and LabCorp. 
 1.40 “Patents” shall mean all existing patents and patent applications and all patent applications hereafter filed,
including any continuation, continuation-in-part, division, provisional or any substitute applications, any patent issued with respect to any such patent applications, any 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 4 

 reissue, reexamination, renewal or extension (including any supplementary protection certificate) of any
such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all foreign counterparts of any of the foregoing. 
 1.41 “Permitted Sublicensees” shall have the meaning set forth in Section 2.6 of this Agreement. 
 1.42 “Person” shall mean any individual, corporation, partnership, association, joint-stock company, trust, unincorporated organization or government or political subdivision thereof.

 1.43 “Regulatory Approval” shall mean any and all approvals, clearances or other authorizations of any
Governmental Authority in the Territory necessary for commercial sale of in vitro diagnostics and/ or new drug products intended for human use, including, without limitation and where applicable, approval of labeling and manufacturing. 

1.44 “Regulatory Authority” shall mean any Governmental Authority with jurisdiction over in vitro diagnostics and/or new
drug products intended for human use in the Territory, including in the United States the FDA. 
 1.45 “Regulatory
Plan” shall have the meaning set forth in Section 4.3 of this Agreement. 
 1.46 “Reimbursement
Plan” shall have the meaning set forth in Section 5.4 of this Agreement. 
 1.47 “Standards for
Commercial Demand” shall mean (i) with respect to the [    *    ] form of the [    *    ]: the [    *    ] that is
expressly stated as a “Standard for Commercial Demand” in the [    *    ], and (ii) with respect to the [    *    ] form of the
[    *    ]: the [    *    ] that is expressly agreed upon by the parties in writing as a “Standard for Commercial Demand” prior to commercial launch of the
[    *    ]. 
 1.48 “Technology Transfer” means the transfer of
technical and regulatory information by LabCorp that is necessary to enable ARCA to perform or have performed, or manufacture or have manufactured, the Commercial Platform in a manner that is acceptable to both Parties (and is agreed to by both
Parties as part of the Commercial Plan). The Technology Transfer provisions in the Commercial Plan may contain provisions to protect the confidentiality, proprietary nature, and use of any trade secrets, proprietary information, or other
intellectual property of LabCorp, and provisions intended to compensate LabCorp for the value of the information being transferred (through royalties or otherwise). 
 1.49 “Territory” shall mean the United States of America and its territories. 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 5 

 1.50 “Third Party” shall mean any person or entity that is not a Party or
an Affiliate of any Party to this Agreement. 
 1.51 “Trademark” shall have the meaning set forth in
Section 4.6 of this Agreement. 
 1.52 “UC” shall mean the University of Cincinnati. 
 1.53 “UC Licenses” shall mean certain licenses granted by the UC in and to certain intellectual property relating pursuant
to that certain License and Option Agreement dated August 16, 2004, as amended March 8, 2006 and June 23, 2006 between CardioDx and UC, and that certain License and Option Agreement dated August 10, 2004, as amended March 8,
2006 and June 23, 2006, between CardioDx and UC. 
 1.54 “Valid Claim” shall mean (a) an issued and
unexpired claim within the ARCA Patent that has not been held unpatentable, invalid or unenforceable by a court or other government agency of competent jurisdiction and has not been admitted to be invalid or unenforceable through reissue,
re-examination, disclaimer or otherwise, or (b) a claim in a pending application within the ARCA Patent, unless such application has been pending for more than 42 months from the date of the first office action. 
 ARTICLE II 
 LICENSE GRANTS; EXCLUSIVITY 
 2.1 Sublicense of Rights Under CardioDx Agreement. Subject to and in
accordance with the other provisions of this Agreement, ARCA hereby grants to LabCorp (and to those Affiliates listed on Exhibit A hereto, subject to Section 2.8 below) an exclusive sublicense to ARCA’s rights under the
CardioDx Agreement to make, have made, use, sell, offer for sale, and import the Diagnostic Tests in the Territory for use in the Field. LabCorp shall have the option, at any time during the term of this Agreement, to negotiate and obtain a license
directly from CardioDx (instead of through ARCA) with respect to the rights currently sublicensed to LabCorp pursuant to this Section 2.1. In the event LabCorp elects to do so, LabCorp will notify ARCA in writing, in which case
[    *    ]. 
 2.2 License to ARCA Technology. Subject to and in accordance with
the other provisions of this Agreement, ARCA hereby grants to LabCorp and its Affiliates and LabCorp and its Affiliates hereby accept an exclusive (except as to ARCA solely for purposes of internal research and ARCA-sponsored clinical trials, in
which ARCA, an academic institution, or a laboratory that is not CLIA-approved performs the Diagnostic Tests, but expressly excluding research and clinical trials for third parties), royalty free license, limited to diagnostic rights only, to the
ARCA Technology (including without limitation the right to practice the processes contained within Valid Claims) to make, have made, perform, use, sell, offer for sale, and import the Diagnostic Tests in the Territory for use in the Field, and an
exclusive (except as to ARCA solely for purposes of marketing LabCorp’s Commercial Platform in accordance with the Marketing and Sales Plan, and all applicable legal requirements), royalty free license to use the 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 6 

 Trademark in connection with marketing and sales activity related to the Diagnostic Tests. These licenses to
the ARCA Technology and the Trademark convey no rights to the manufacture, use, sale or other commercialization of the Drug Product, which rights are expressly reserved exclusively to ARCA, and shall not interfere with or restrict, in any way,
ARCA’s rights, or those of its licensees, to develop, make, have made, perform, use, sell, offer for sale or import the Drug Product. 
 2.3 Sublicenses of Third Party Rights to LabCorp. LabCorp understands that the rights that may be granted hereunder include certain rights sublicensed to ARCA pursuant to the CardioDx Agreement and
the UC Licenses, and that the sublicense granted to LabCorp in Section 2.1 is subject and subordinate to the terms and conditions of the UC Licenses and the CardioDx Agreement, except that LabCorp is subject to a different royalty rate
and other non-royalty obligations, as referenced in Section 7.1 and contained in the CardioDx Agreement, than are set forth in the UC Licenses. 
 2.4 No Implied Licenses. Except as specifically set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, to any
information disclosed to it under this Agreement or under any Patents or Know-How Controlled by the other Party or its Affiliates. 
 2.5 Exclusivity. During the term of this Agreement, ARCA shall not grant the license rights set forth in this Article II to any Third Party, except as permitted by this Agreement (including, without limitation,
Section 10.5). ARCA acknowledges that it is not reserving any license or rights to use or otherwise exploit the ARCA Technology with respect to Diagnostic Tests in the Territory for use in the Field (except as to ARCA solely for purposes
of internal research and ARCA-sponsored clinical trials, in which ARCA, an academic institution, or a laboratory that is not CLIA-approved performs the Diagnostic Tests, but expressly excluding research and clinical trials for third parties) or any
of its rights under the CardioDx Agreement to make, have made, perform, use, sell, offer for sale, or import Diagnostic Tests in the Territory for use in the Field. 
 2.6 Sublicensing by LabCorp. The Third Parties listed on Exhibit B hereto shall be deemed “Permitted Sublicensees”, subject to the approval of CardioDx. ARCA agrees to use
reasonable efforts to obtain, prior to the earlier of (a) ninety (90) days after the Effective Date or (b) written agreement by the Parties on the Commercial Plan, the written approval of CardioDx for the Third Parties listed on
Exhibit B hereto to be Permitted Sublicensees. In the event ARCA fails to obtain such written approval within the time period specified above, ARCA shall immediately notify LabCorp in writing. LabCorp shall be permitted to designate at least
one Third Party from the list of Permitted Sublicensees, as a prospective additional sublicensee of the licenses granted to LabCorp under Sections 2.1 and 2.2 of this Agreement to make, have made, use, sell, offer for sale, and import
the Diagnostic Tests in the Territory, and of the use of the Trademark in connection therewith, by giving written notice to ARCA. The terms of a sublicense granted by LabCorp hereunder shall be subject to ARCA’s prior written approval (which
shall not be unreasonably withheld) and shall include a requirement that (a) the sublicensee use its commercially reasonable efforts to bring the subject matter of the sublicense into commercial use as quickly as is reasonably possible,
consistent with sound and reasonable business practices and judgment and in compliance with the Commercialization Plans (as

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 7 

 
applicable), (b) the sublicense is subject and subordinate to the terms and conditions of this Agreement, (c) the sublicense cannot be further sublicensed and (d) the sublicense
shall terminate upon termination or expiration of this Agreement as provided in Article X. Copies of all sublicense agreements shall be provided to ARCA within fifteen (15) days of execution thereof. LabCorp hereby assumes responsibility
for the performance of all obligations so imposed on its sublicensees by this Agreement and will itself pay and account to ARCA for all payments and reports due under this Agreement which may accrue by reason of the operations of each sublicense, as
if it were LabCorp’s own commercial activity. 
 2.7 Right of First Refusal for Canada. During the term of this
Agreement, ARCA shall provide LabCorp with written notice prior to the first occasion that ARCA solicits any interest in, makes any offers for, or engages in any negotiations with any other Persons with respect to, any rights to make, have made,
perform, use, sell, offer for sale, or import Diagnostic Tests (in the form of a Homebrew Assay, IVD Product or IVD Kit) in Canada for use in the Field. Upon LabCorp’s receipt of such notice and for a period of ninety (90) days thereafter,
ARCA agrees to have good faith, exclusive negotiations with LabCorp regarding a possible license or other transfer of such rights to LabCorp with respect to Canada (under terms no less favorable than those set forth in this Agreement), unless
LabCorp notifies ARCA that it is not interested in such rights. If no agreement is entered into between ARCA and LabCorp during this ninety (90) day period, ARCA shall be permitted to negotiate with Third Parties and enter into agreement(s)
with Third Parties relating to such rights in Canada with terms that are no less favorable to ARCA than those offered to LabCorp. However, ARCA shall not negotiate or enter into agreement(s) with Third Parties with terms that are less favorable to
ARCA than those offered to LabCorp, unless ARCA first offers such terms to LabCorp in writing and allows LabCorp a period of thirty (30) days after receipt of such terms to accept or reject such terms. 
 2.8 Rights of LabCorp Affiliates under CardioDx Agreement. The LabCorp Affiliates listed on Exhibit A hereto shall be included
within the sublicense granted under Section 2.1 subject to the approval of CardioDx. ARCA agrees to use reasonable efforts to obtain, prior to the earlier of (a) ninety (90) days after the Effective Date or (b) written
agreement by the Parties on the Commercial Plan, the written approval of CardioDx for these LabCorp Affiliates (and, in addition, wholly-owned Affiliates that LabCorp may acquire in the future) to be included within the sublicense granted under
Section 2.1. In the event ARCA fails to obtain such written approval within the time period specified above, ARCA shall immediately notify LabCorp in writing. In the event that ARCA obtains such agreement for future-acquired Affiliates,
ARCA agrees to amend this Agreement to include such Affiliates in the license grant. 
 ARTICLE III 
 GENERAL; DIAGNOSTICS COMMITTEE 
 3.1 General. Each Party agrees to use commercially reasonable efforts to execute and perform those components of the Commercialization Plans for which it is responsible in a timely manner, to
maintain and utilize its staff and facilities consistent with such undertaking, and to cooperate with the other Party in the activities conducted under this Agreement. The personnel assigned to this Agreement shall have experience which is relevant
to the Field and a background suitable to the difficulty of the tasks involved. Each of the Parties will endeavor to provide continuity of involvement in projects by key personnel assigned to the Agreement. 
  

 Development, Commercialization and Licensing Agreement-Confidential-Page 8 

 3.2 Diagnostics Committee. In accordance with the terms and conditions of this
Agreement, the Parties shall consult with a committee (the “Diagnostics Committee”) which shall be comprised of an equal number of representatives from each of ARCA and LabCorp, with the total number of committee members not to
exceed six members, unless otherwise agreed by the Parties. The Diagnostics Committee may elect to add one representative of the Third Parry vendor (if any) retained by LabCorp to assist in the development of the IVD Kit. Each of ARCA and LabCorp
shall, as soon as possible and in any case no later than thirty (30) days following the Effective Date, appoint its representative members to the Diagnostics Committee and give written notice thereof to the other Party. The Diagnostics
Committee will be co-chaired by one co-chairperson designated by ARCA and one co-chairperson designated by LabCorp. LabCorp’s initial designee as a co-chairperson is [    *    ], and ARCA’s initial
designee as a co-chairperson is [    *    ]. Members of the Diagnostics Committee shall serve in such capacities, on such terms and conditions, and for such duration as shall be determined by the Party
appointing same. Each Party may designate an alternate member or co-chairperson to serve temporarily in the absence of a permanent member or co-chairperson designated by such Party. Each Party may from time to time upon prior written notice change
its co-chairperson or its representative members on the Diagnostics Committee. 
 3.3 Meetings of the Diagnostics Committee.
Unless otherwise agreed by the Parties from time to time, the Diagnostics Committee will meet at such times and places as determined by the Parties on no less frequently than a quarterly basis. The Diagnostics Committee will endeavor to hold
such quarterly meetings in person, but may conduct meetings in person or by conference telephone or video conference, and may also act without a meeting if a written consent to an action or decision is signed by each co-chair (or his/her written
designee member of the Diagnostics Committee). The co-chairs will keep minutes reflecting actions taken at meetings, which the Parties will use their commercially reasonable efforts to cause to be circulated and signed by each co-chair (or his/her
written designee member of the Diagnostics Committee) within thirty (30) days following each meeting. The Diagnostics Committee may amend or expand upon the foregoing procedures for its internal operation at a meeting of the Diagnostics
Committee or by written consent of the Diagnostics Committee as aforesaid. 
 3.4 Functions and Powers of the Diagnostics
Committee. The Diagnostics Committee shall perform the following functions: 
 (a) consult with ARCA on the design
and development of the Regulatory Plan, and with LabCorp on the design and development of the Commercial Platform, the Commercial Plan, the Marketing and Sales Plan and the Reimbursement Plan in the manner contemplated by this Agreement; 

(b) consult with LabCorp on development of the IVD Kit; 
 (c) consult on co-marketing plans for the IVD Product and IVD Kit and activities between the Parties; 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 9 

 (d) following commercial launch of the Drug Product, consult on the commercial and
sales progress of the IVD Product and IVD Kit; and 
 (e) perform such other functions as appropriate to further the
purposes of this Agreement as determined by the Parties, except that the development, commercialization, and promotion of the Homebrew Assay shall be the sole responsibility of LabCorp, not within the scope of functions and powers of the Diagnostic
Committee, and shall be conducted in conformance with all applicable laws and regulations as interpreted and enforced by Regulatory Authorities. 
 3.5 Diagnostics Committee Actions or Decisions. Actions or decisions by the Diagnostics Committee pursuant to the terms of this Agreement shall be taken or made by the unanimous vote of the
co-chairpersons of the Diagnostics Committee, who shall each represent the consolidated position of his/her fellow representative members appointed by his/her respective Party. 
 3.6 Obligation of Parties. ARCA and LabCorp shall provide the Diagnostics Committee and its authorized representatives with
reasonable access during regular business hours to all records and documents relating to this Agreement, which it may reasonably require in order to perform its obligations hereunder; provided that if such documents are under a bona fide obligation
of confidentiality to a Third Party, then ARCA or LabCorp, as the case may be, may withhold access thereto to the extent necessary to satisfy such obligation. 
 3.7 Limits of Powers of the Diagnostics Committee. The Diagnostics Committee shall only have such powers as are specifically delegated to it hereunder or as the Parties may otherwise agree in
writing from time to time. 
 3.8 Disputes. If the Diagnostics Committee fails to reach agreement on a matter before it
for consideration, then either Party may by written notice to the other Party invoke the dispute resolution procedure set forth in Article XII, unless otherwise indicated in this Agreement. 
 3.9 Agendas. Each Party will use commercially reasonable efforts to notify the other at least three business days prior to the date
of a meeting of the Diagnostics Committee, proposing the agenda items it wishes to discuss at such meeting. Notwithstanding the foregoing, the Diagnostics Committee shall be free to consider any matter related to this Agreement which is within the
scope of its responsibilities and is brought to its attention by any Party at any meeting. 
 ARTICLE IV 
 DEVELOPMENT PHASE 
 4.1 Scope. LabCorp shall commence and diligently pursue the development of the Commercial Platform, as more particularly set forth in this Article IV, and use commercially reasonable efforts to: 1) legally market the Commercial
Platform within a time period thereafter to be agreed upon by the Parties, but in any case by the time the Drug Product is first available for commercial sale in the Territory; and 2) obtain Regulatory Approval of the Commercial Platform by the date
of first commercial sale of the Drug Product or as soon as reasonably practical thereafter. LabCorp will have executive and financial responsibility for development of the Commercial Platform. The Parties will cooperate in an effort to obtain
Regulatory Approval as described below. 
  

 Development, Commercialization and Licensing Agreement-Confidential-Page 10 

 4.2 Development of Commercial Platform. LabCorp will be responsible for using
commercially reasonable efforts to design and develop the Commercial Platform. The Parties anticipate that the Commercial Platform will utilize the least-intrusive procedure that is practical and commercially reasonable, such as a blood-based and/or
buccal swab procedure. LabCorp will use commercially reasonable efforts to obtain Regulatory Approval of the Commercial Platform (i.e., as an IVD Product) prior to the first commercial sale of the Drug Product in the Territory, but the Parties
acknowledge that the Commercial Platform may be available commercially only in the form of a Homebrew Assay, that has not received Regulatory Approval, by the time of first commercial sale. The Parties anticipate initially seeking Regulatory
Approval of the Commercial Platform as a centralized, laboratory procedure, and later as an IVD Kit that can be performed in a de-centralized fashion by LabCorp or by Third Parties, as discussed below. The Parties will use reasonable commercial
efforts to obtain a Regulatory Approval of the Commercial Platform that will permit (among other things) ARCA and LabCorp to market the usefulness of the Diagnostic Tests in determining the appropriateness of, and the clinical outcomes expected from
use of the Drug Product, and to reference the Commercial Platform in the labeling of the Drug Product. ARCA will consult with LabCorp, as needed, in order to facilitate the development of the Commercial Platform. The Commercial Platform, and any
amendments or modifications thereto, will be subject to ARCA’s commercially reasonable approval. 
 4.3 Regulatory Plan.
ARCA, in consultation with LabCorp, will develop a regulatory plan (the “Regulatory Plan”). The purpose of the Regulatory Plan is to provide the Parties with an outline of the overall strategy and timelines, and identifying
documentation necessary to obtain, Regulatory Approval of the Drug Product and the Commercial Platform, and the degree to which the Regulatory Approval of the Commercial Platform will be integrated with that of the Drug Product. The development,
approval, commercialization and promotion of the Drug Product shall be the sole responsibility of ARCA. The Parties acknowledge that, based on the guidance of Regulatory Authorities, Regulatory Approval of the Drug Product and the Commercial
Platform may be sought through submissions to Regulatory Authorities under a single application, whether as a Combination Product or through some other combination of use as may be permitted or required by Regulatory Authorities, or under separate
applications. To the extent that Regulatory Approval of the Drug Product and the Commercial Platform are sought through separate applications, consistent with the guidance of Regulatory Authorities, LabCorp and ARCA agree to develop the Regulatory
Plan to support each other’s separate submissions; provided, that the final content of the Plan shall remain within ARCA’s control and discretion, and further provided that those portions of the Regulatory Plan concerning the Diagnostic
Tests and the design and development of the Commercial Platform (including the IVD Product and the IVD Kit), and any amendments or modifications thereto, will be subject to LabCorp’s commercially reasonable approval. The marketing of the
Homebrew Assay, if made available, shall be solely the responsibility of LabCorp and shall not be inconsistent with the Regulatory Plan for the commercialization of the IVD Product and IVD Kit. The Regulatory Plan will be completed within one
hundred twenty (120) days of the date hereof and will clearly indicate: 
 (a) Whether Regulatory Approval will be
sought in the United States for the Drug Product and the Commercial Platform under a single application or under separate applications; 
  

 Development, Commercialization and Licensing Agreement-Confidential-Page 11 

 (b) Alternative strategies for obtaining Regulatory Approval of the Drug Product and
the Commercial Platform, as may be reasonable; 
 (c) The [    *    ] (where
applicable), estimated timelines, duties and parties responsible for each stage of seeking Regulatory Approval for the Drug Product and the Commercial Platform, including the timing of each submission required to obtain Regulatory Approval;

 (d) Proposed labeling for the Drug Product and the Commercial Platform; 
 (e) Procedures for providing documentation to each Parry of written or oral communications to or from Regulatory Authorities related
to Regulatory Approval of the Drug Product and the Commercial Platform; and 
 (f) The projected date for commercial
launch in the Territory of the Drug Product and the Commercial Platform. 
 4.4 Regulatory Approval; Assistance with
Regulatory Submissions 
 (a) If Regulatory Approval of the Drug Product and the Commercial Platform is initially
sought under one application, whether as a Combination Product or through some other combination of use as may be permitted or required by Regulatory Authorities, ARCA will have primary responsibility for the preparation and submission of the single
application to Regulatory Authorities. In the event Regulatory Approval of the Drug Product and the Commercial Platform is sought through separate applications for each product, ARCA will have primary responsibility for the preparation and
submission of all regulatory applications pertaining to the Drug Product, and LabCorp will have primary responsibility for the preparation and submission of all regulatory applications or notifications pertaining to the Commercial Platform. In any
consultation or cooperation between the Parties called for in this Section 4.4, the Parties agree to provide such consultation and cooperation in a reasonable and timely manner. 
 (b) If Regulatory Approval of the Drug Product and the Commercial Platform is initially sought under one application, whether as a
Combination Product or through some other combination as may be permitted or required by Regulatory Authorities, LabCorp will consult with ARCA and support the preparation and submission of such application and will have responsibility for providing
the analytical validation of the Commercial Platform to ARCA (i.e., the precision or reproducibility, accuracy, limit of detection, traceability, and potential interferences) for use in such application. ARCA will be responsible for validating the
clinical utility of the Commercial Platform when used with the Drug Product in support of such application. 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 12 

 (c) Regardless of whether or not Regulatory Approval is sought under one application
or through separate applications, the Parties agree to the following: 
 (i) LabCorp will use reasonable
commercial efforts to: 1) develop the Commercial Platform and have it available for use with the Drug Product by the time the Drug Product is first legally marketed in the Territory, and 2) submit to Regulatory Authorities an application or
notification to obtain Regulatory Approval of the Commercial Platform by the same date or as soon thereafter as reasonably practical. The Parties acknowledge that Regulatory Approval is not guaranteed and is subject to the discretion of Regulatory
Authorities as permitted by law. Nothing in this Agreement is intended to preclude or restrict LabCorp from commercializing the Commercial Platform before Regulatory Approval is obtained for the Drug Product pursuant to applicable law, as
interpreted and enforced by Regulatory Authorities. 
 (ii) Each Party shall consult with the Diagnostics
Committee on a regular basis on its progress in seeking Regulatory Approval, and will obtain the reasonable approval of the Diagnostics Committee of its regulatory strategy. 
 (iii) Each Party shall periodically consult with Regulatory Authorities, including the FDA, as part of its efforts to seek
Regulatory Approval of the Drug Product and the Commercial Platform (regardless of whether Regulatory Approval is pursued under a single or separate application) and coordinate such consultations with the other Party and allow representatives of the
other Party to participate in any such consultations. 
 (iv) ARCA will notify LabCorp in writing from time to
time of its progress with respect to its efforts in obtaining Regulatory Approval of the Drug Product and will provide LabCorp, on an ongoing basis, with copies of material correspondence relating thereto. 
 (v) Each Party shall notify the other Party of any oral or written communications to or from Regulatory Authorities,
including the FDA, on matters relating to the Commercial Platform, and shall provide the other Party with copies of any such communications reasonably promptly and give the other Party the right to review and participate in any response to any such
communications. 
 (d) The Parties will cooperate in supporting all regulatory submissions that involve the Drug Product
and the Commercial Platform, including submissions made separately or under one application, seeking Regulatory Approval, and will coordinate any substantial contacts with Regulatory Authorities, including the FDA, that involve seeking Regulatory
Approval of the Commercial Platform. In addition to the activities described in subparagraphs (a), (b), and (c) above, this shall include: 
 (i) Consultation with and participation by LabCorp on a reasonable basis on the content of any submissions to Regulatory Authorities related to obtaining marketing approval of the Drug Product as it
pertains to the Commercial Platform,

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 13 

 
including the incorporation of LabCorp’s ongoing work for ARCA involving confirmation of the [    *    ] results into the marketing application
submitted to Regulatory Authorities. 
 (ii) The opportunity to attend or participate in all substantial
contacts, including meetings and conference calls, between ARCA and any Regulatory Authority within the Territory, including any Advisory Committee of the FDA, relating to Regulatory Approval of the Commercial Platform. ARCA will give LabCorp
commercially reasonable notice of all such contacts, including anticipated contacts. 
 (e) Unless otherwise agreed by
the parties, (i) ARCA shall be the named holder of all submissions relating to the Regulatory Approval of the Drug Product and, to the extent permitted by applicable law, [    *    ] shall solely own all
such submissions and Regulatory Approvals; including the Regulatory Approvals of both the Drug Product and the Commercial Platform, if they are approved pursuant to a single application, and (ii) LabCorp shall be the named holder of all
submissions relating to the Regulatory Approvals of the Commercial Platform and, to the extent permitted by applicable law, LabCorp shall solely own all such submissions and Regulatory Approvals for the Commercial Platform, including any Regulatory
Approvals for the IVD Product portion of a Combination Product if approved pursuant to separate applications. 
 4.5 IVD Kit.
LabCorp will use commercially reasonable efforts to seek Regulatory Approval for the Commercial Platform as an IVD Kit following the initial Regulatory Approval of the IVD Product, in accord with the Commercial Plan. LabCorp intends to use the
assistance of a Third Party to develop and seek Regulatory Approval for the IVD Kit, and, if necessary, ARCA will use commercially reasonable efforts to enter into a sublicense with such Third Party containing terms sufficient to permit the
successful development and commercialization of the IVD Kit as contemplated by this Agreement. 
 4.6 Trademark for the
Diagnostic Tests. ARCA will be primarily responsible for identifying a trademark to be used in connection with the marketing, sale, distribution and promotion of the Commercial Platform in the Territory (the “Trademark”). The
Trademark shall be acceptable to LabCorp. As soon as practical, and prior to first commercial sale of the Drug Product, and to the extent it is legally able to do so, ARCA will file and prosecute a trademark application with the United States Patent
and Trademark Office to try to obtain a federal trademark registration for the use of the Trademark in connection with the marketing, sale, distribution and promotion of the Commercial Platform, including, if applicable, the IVD Product. ARCA shall
be responsible for, and pay all fees and costs relating to, the prosecution, maintenance and defense of the Trademark. Subject to its reasonable commercial judgment, ARCA will use reasonable commercial efforts to obtain Regulatory Approval to
include the Trademark in the labeling for the Drug Product, and ARCA agrees to include the Trademark in the labeling for the Drug Product if permitted to do so. ARCA shall own all right, title and interest in and to the Trademark, subject to
LabCorp’s license under Section 2.2; provided that ARCA shall have the right to reasonably approve all such uses of the Trademark by LabCorp. Each Party shall notify the other Party promptly upon learning of any actual, alleged, or
threatened infringement of the Trademark or of any unfair trade practices, trade dress imitation, passing off of counterfeit goods, or like offenses. 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 14 

 ARTICLE V 
 COMMERCIALIZATION PHASE 
 5.1 Scope. Except as otherwise agreed by
the Parties, LabCorp shall be primarily responsible for using commercially reasonable efforts to establish, implement and fund all aspects of the commercialization of the Commercial Platform in the Territory pursuant to the terms and conditions of
this Agreement and in compliance with all applicable laws and regulations as interpreted and enforced by Regulatory Authorities. 
 5.2 Commercial Plan. LabCorp shall develop, in consultation with the Diagnostics Committee, a commercial plan for the commercialization of the Commercial Platform in the Territory (the “Commercial Plan”), except that
LabCorp shall have sole responsibility for marketing a Homebrew Assay, which shall not be inconsistent with the Commercialization Plans. The Commercial Plan will be subject to change based on the guidance of Regulatory Authorities and on the terms
and conditions of Regulatory Approval and will be updated with more detailed and specific descriptions following receipt of Regulatory Approval. The Commercial Plan, and any amendments or modifications thereto, will be subject to ARCA’s
commercially reasonable approval. The initially approved Commercial Plan will be completed within one hundred twenty (120) days of the date hereof and will include the following elements, among others: 
 (a) Specification of the Commercial Platform and description of the process and the timeline for development and commercial launch of
the Commercial Platform. 
 (b) A description of the testing process and systems, including the incorporation of the
Commercial Platform into LabCorp’s existing manufacturing, supply, production, laboratory and administrative capabilities, facilities and processes, and the minimum quality, production, distribution and performance standards that the Commercial
Platform will satisfy from commercial launch of the Drug Product. 
 (c) A description of LabCorp’s plans for
sublicensing rights in the Diagnostic Tests to additional partners pursuant to the terms of this Agreement. 
 (d) A
definition of the Standards for Commercial Demand with respect to the [    *    ] form of the [    *    ]. 
 (e) The terms and conditions for [    *    ]. 
 The Commercial Plan will also include a description of LabCorp’s plans for incorporation of the Commercial Platform into other diagnostic products,
such as broader diagnostic panels for the Drug Product and for heart failure; provided, however, that while ARCA shall consult on such plans, the content of such plans shall remain within the sole discretion of LabCorp. 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 15 

 5.3 Marketing and Sales Plan. LabCorp, in consultation with the Diagnostics
Committee, will develop a marketing and sales plan for the promotion, advertising, education, marketing, launch, sale and/or distribution of the IVD Product and IVD Kit in the Territory pursuant to the conditions of Regulatory Approval and all
activities incident thereto (the “Marketing and Sales Plan”). The Marketing and Sales Plan, and any amendments or modifications thereto, will be subject to [    *    ]. A proposed Marketing
and Sales Plan will be distributed [    *    ] within approximately 90 days of [    *    ] and an approved Marketing and Sales Plan shall be completed within 180 days of
[    *    ]. The Marketing and Sales Plan will specify the marketing and sales programs that LabCorp will initiate in connection with the commercial launch of the IVD Product and IVD Kit and will provide for
appropriate integration of the IVD Product and IVD Kit into LabCorp’s existing sales and marketing infrastructure. The Marketing and Sales Plan will include the following elements, among others:
[    *    ] 
 The Marketing and Sales Plan will also include information regarding the possible
development of broader diagnostic panels for the Drug Product or its indications, that include the Commercial Platform; provided, however, that such information shall be determined in the sole discretion of LabCorp. 
 The Marketing and Sales Plan shall be updated, as appropriate and in consultation with the Diagnostics Committee, no later than 90 days
prior to the anticipated date of commercial launch of the Drug Product. 
 5.4 Reimbursement Plan.
[    *    ] will develop a payor reimbursement plan for the Commercial Platform in the Territory (the “Reimbursement Plan”). The Reimbursement Plan, and any amendments or modifications
thereto, will be subject to [    *    ]. A proposed Reimbursement Plan will be circulated to [    *    ] within approximately 90 days of the date hereof, and an approved
Reimbursement Plan will be completed within 180 days of the date hereof, and will be updated, as appropriate and in consultation with [    *    ], no later than 90 days prior to the anticipated date of
commercial launch of the Drug Product. The Reimbursement Plan will specify the processes and timelines for [    *    ] as well as [    *    ], for the Commercial
Platform. [    *    ]. 
 5.5 Commercialization Efforts. LabCorp shall use its
commercially reasonable efforts to make, market, advertise, promote, distribute and sell the Commercial Platform [    *    ] in accordance with the Commercialization Plans, the provisions of this Agreement,
and all applicable laws and regulations as interpreted and enforced by Regulatory Authorities. The Commercialization Plans shall be deemed incorporated into this Agreement. LabCorp will use commercially reasonable efforts to conduct the
commercialization activities relating to the Commercial Platform in accordance with the timetables and other provisions of the Commercialization Plans and will integrate such activities into LabCorp’s existing sales, marketing and distribution
infrastructure to support the sale and distribution of the IVD Product and IVD Kit throughout the Territory. 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 16 

 LabCorp shall have the right to grant one or more exclusive or non-exclusive marketing,
sales, sales agency and/or distribution rights, with respect to any rights conferred upon LabCorp under this Agreement after receiving the prior written consent of ARCA, which consent will not be unreasonably withheld. Any permitted grant by LabCorp
of marketing, sales, sales agency and/or distribution rights shall be pursuant to a written agreement, the terms and conditions of which shall be consistent with those of this Agreement, and a true and complete copy of which shall be immediately
supplied to ARCA upon execution and delivery. 
 ARCA shall use commercially reasonable efforts to make, market, advertise,
promote, distribute and sell the Drug Product and to maximize sales of the Drug Product for use throughout the Territory. 
 5.6 Advertising and Education. All advertising and educational materials relating to the Commercial Platform and related materials shall be prepared by LabCorp (or its subcontractors), and such materials related to the IVD Product or
IVD Kit shall be subject to reasonable approval by ARCA and any such materials for different versions of the IVD Product or IVD Kit shall be consistent. Any such materials for the Homebrew Assay shall not be inconsistent with materials relating to
the Drug Product, the IVD Product, or the IVD Kit, or to applicable laws as interpreted and enforced by Regulatory Authorities. Where appropriate or necessary, all packaging, labeling and advertising and educational materials for the Commercial
Platform shall contain the legend, “Manufactured under license from ARCA Discovery Inc., Denver, Colorado, U.S.A.” 
 5.7 Training Program. LabCorp shall develop training programs relating to the Commercial Platform for its sales forces and for any Third Parties engaged in selling or promotion. The Parties agree to utilize such training programs on
an ongoing basis to assure a consistent, focused promotional strategy. Training shall be carried out reasonably in advance of the time at which Regulatory Approval is expected. As additional members are added to LabCorp’s sales forces, training
will be given to groups of the newly selected members. The costs of training such personnel and the preparation of related materials shall be borne solely by LabCorp. 
 5.8 Consultation with the Diagnostics Committee. LabCorp shall consult with the Diagnostics Committee from time to time, but no less frequently than quarterly, on matters relating to the
commercialization of the Commercial Platform in the Territory, including, as appropriate, the progress of LabCorp’s commercialization activities in the Territory, coordination of reimbursement procedures and training, regulatory matters,
technical support, product positioning, marketing and advertising and other activities relating to the commercialization of the Commercial Platform in the Field prior to and following commercial launch. The Diagnostics Committee will be the
principal provider of input from ARCA to LabCorp on the Commercialization Plans and will be afforded the opportunity to consult with LabCorp representatives in the preparation of all material marketing, sales, distribution, advertising, educational
and promotional plans for the Commercial Platform, review all details, and provide LabCorp with comments on such plans. 
  

 Development, Commercialization and Licensing Agreement-Confidential-Page 17 

 ARTICLE VI 
 MANUFACTURE AND SUPPLY 
 6.1 Manufacture and
Supply. LabCorp shall have sole responsibility, at its cost, for the manufacture, including manufacture by a Third Party, of the IVD Product and IVD Kit and the supply of the IVD Product and IVD Kit and promotional materials, and until such time
as the IVD Product obtains Regulatory Approval in the Territory, for performing Homebrew Assays, necessary to commercialize the Commercial Platform in accordance with the specifications and standards set forth in the Commercial Plan. LabCorp shall
comply with all applicable current GMP regulations, as interpreted and enforced by Regulatory Authorities, including using commercially reasonable efforts to ensure the compliance of any Third Party vendor in the manufacture and supply of the IVD
Kits. At all times during the term of this Agreement after the Commercial Platform is made commercially available, LabCorp shall use reasonable commercial efforts to ‘ensure an adequate commercial supply of the Commercial Platform (whether in
the form of Homebrew Assays, IVD Product or IVD Kits) in the Territory subject to the conditions of Regulatory Approval and to ensure an adequate manufacturing capacity to meet the forecast demand on a timely basis, including through the
establishment of alternative supply sources if necessary. 
 6.2 Failure to Supply. In the event that, following
Regulatory Approval of the Drug Product, [    *    ] in a manner that meets the Standards for Commercial Demand, [    *    ]. If the Parties fail to agree on such
[    *    ], and if [    *    ] continues to be unable to meet the Standards for Commercial Demand, [    *    ] shall have the
right to [    *    ] is not able to perform or supply in accordance with the Standards for Commercial Demand, or such greater amount (and for such duration of time) as is reasonably necessary to make it
economically practical for [    *    ] to undertake performance or supply of the [    *    ]. All [    *    ] performed or
manufactured by or on behalf of [    *    ] and other obligations assumed by [    *    ] pursuant to this Section 6.2 shall be performed or manufactured in
accordance with the specifications agreed to in the Commercialization Plans. All direct and indirect costs incurred by [    *    ] or other liability arising in connection with any such performance or
manufacture of the [    *    ] by or on behalf of [    *    ] or other obligations assumed under this Section 6.2 shall be borne solely by
[    *    ]. [    *    ] The provisions of this Section 6.2 are in addition to any other remedies provided to
[    *    ] under Section 10. 
 ARTICLE VII 
 PAYMENTS 
 7.1 Royalties and Fees Payable by LabCorp. Subject to the terms and conditions of this Agreement, and in further consideration of the rights granted by ARCA hereunder, LabCorp shall assume the royalty and all other fee obligations of
ARCA under the CardioDx Agreement arising out of the sale or other disposition by LabCorp of the Diagnostic Tests. LabCorp shall pay directly to CardioDx all such royalties and other fees, calculated as set forth in Section 3.3 of the CardioDx
Agreement, in accordance with the payment, reporting, auditing and 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 18 

 other terms applicable to such royalties and other fees contained in Sections 3.3 through 3.6 of the
CardioDx Agreement. LabCorp shall send ARCA copies of all notices, reports and other correspondence relating to its payment of such royalties and other fees to CardioDx at the time such notices, reports and other correspondence are sent to CardioDx.

 7.2 Milestone Equity Issuances. Subject to the terms and conditions of this Agreement, and in further consideration of
the rights granted by ARCA hereunder, ARCA shall issue a total of 100,000 shares of its common stock to LabCorp, which shares shall be issued subject to a Stock Restriction Agreement, mutually acceptable to the Parties, that will provide for the
following vesting schedule: 
 (a) 50,000 shares of the common stock in this grant shall vest upon
[    *    ]. 
 (b) 50,000 shares of the common stock in this grant shall vest
upon [    *    ]. 
 7.3 Records and Audit Rights. 
 (a) LabCorp shall keep full, true and accurate books of accounts and other records containing all information and data which may be
necessary to ascertain and verify [    *    ] for a period of three years following the year to which such records relate. During the term of this Agreement and for a period of three years following its
termination, ARCA, CardioDx and UC shall have the right to audit, or have an agent, accountant or other representative audit (in each case in a manner that does not unreasonably interfere with LabCorp’s operations) such books, records and
supporting data upon fifteen (15) days prior written notice. Any audit shall be at ARCA’s, CardioDx’s or UC’s expense (as applicable), except that LabCorp shall reimburse ARCA, CardioDx or UC for the cost of the audit in the
event that ARCA, CardioDx or UC discovers an underpayment of ten percent (10%) or more of the amount due. Any underpayment of amounts due from LabCorp hereunder shall be paid within thirty (30) days of the delivery of a written
accountant’s report to the Parties. 
 (b) Beginning with first commercial sale of the Drug Product, ARCA shall
provide a written report to LabCorp on a quarterly basis (within sixty days after the end of each calendar quarter) indicating its cumulative net sales of the Drug Product, [    *    ]. ARCA shall keep full,
true and accurate books of accounts and other records containing all information and data which may be necessary to ascertain and verify the net sales of the Drug Product for purposes of [    *    ] for a
period of three years following [    *    ]. During the term of this Agreement until [    *    ] LabCorp shall have the right to audit, or have an agent, accountant or
other representative audit (in each case in a manner that does not unreasonably interfere with ARCA’s operations) such books, records and supporting data upon fifteen (15) days prior written notice. Any audit shall be at LabCorp’s
expense (as applicable), except that ARCA shall reimburse LabCorp for the cost of the audit in the event that LabCorp discovers ARCA has under-reported net sales by ten percent (10%) or more. 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 19 

 ARTICLE VIII 
 INVENTIONS; CONFIDENTIALITY; PUBLICITY 
 8.1
Inventions. All information, discoveries, knowledge, experience, processes, procedures, inventions, devices, skills, Know-How, samples, trade secrets, designs, formulations, specifications, methods, techniques, technical information,
compilations, concepts, developments, inventions and improvements, whether patentable or not, and any associated patent, copyright, trade secret, or other intellectual property rights (“New Inventions”) arising from
[    *    ] shall be owned by [    *    ]. All New Inventions arising from [    *    ] shall be owned by
[    *    ]. All New Inventions arising from [    *    ] shall be owned by [    *    ]. For purposes of the foregoing,
inventorship shall be determined in accordance with U.S. law. [    *    ] agrees that it will execute and deliver all assignments and other documents as may be necessary or appropriate to assign its rights to
[    *    ] Party as contemplated by this Agreement. Subject to the terms and conditions of this Agreement (including the licenses granted hereunder), LabCorp and ARCA shall each retain their respective
unrestricted rights to make, have made, use, sell, have sold, and import, respectively, [    *    ]. 
 8.2 Confidentiality; Exceptions. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that, for the term of this Agreement and for ten years
thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any Information and other materials furnished to it by the other Party pursuant
to this Agreement or any Information relating to Joint Inventions developed during the course of performing this Agreement and assigned to the other Party pursuant to Section 8.1 (collectively, “Confidential Information”),
except to the extent that it can be established by the receiving Party that such Confidential Information: 
 (a) was
already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the other Party and such receiving Party has documentary evidence to that effect; 
 (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving
Party; 
 (c) became generally available to the public or otherwise part of the public domain after its disclosure and
other than through any act or omission of the receiving Party in breach of this Agreement; 
 (d) was disclosed to the
receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the disclosing Party not to disclose such information to others; or 
 (e) was independently developed by the receiving Party without use of the Confidential Information of the disclosing Party.

  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 20 

 8.3 Authorized Disclosure and Use. Each Party may disclose Confidential Information
hereunder to the extent such disclosure is reasonably necessary in filing or prosecuting Patent applications, prosecuting or defending litigation, or complying with applicable governmental regulations, provided that if a Party is required by law or
regulation to make any such disclosure of the other Party’s Confidential Information, it will, except where impracticable for necessary disclosures, give reasonable advance notice to the other Party of such disclosure requirement and will where
applicable use its reasonable efforts to seek confidential treatment of such Confidential Information required to be disclosed. 
 8.4 Survival. This Article VIII shall survive the termination or expiration of this Agreement for a period of ten years. 
 8.5 Termination of Prior Agreement. This Agreement supersedes the Clinical Trials Confidential Disclosure Agreement between the Parties, dated February 27, 2006. All Information exchanged
between the Parties under that agreement shall be deemed Confidential Information and shall be subject to the terms of this Article VIII. 
 8.6 Publicity. The Parties shall consult and coordinate with each other respecting the text and timing of any publicity, press, or news releases or other public announcements or disclosures prior
to issuance thereof regarding the existence or terms of this Agreement and the transactions contemplated hereby; provided, however, that neither Party shall issue any such press releases, announcements or disclosures without the other
Party’s consent, which may not be unreasonably withheld. Except as otherwise explicitly provided in this Agreement, neither Party shall use the name, trademark, trade name or logo of the other for marketing, advertising, or promotional claims
without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may issue such press releases or otherwise make such public statements or disclosures (such as in annual reports to stockholders or filings with the
Securities and Exchange Commission) as it determines, based on advice of counsel, are reasonably necessary to comply with applicable laws and regulations; provided, however, that a Party shall not issue any such press releases or make
such statements or disclosures without the other Party’s prior review and comment: In addition, following any initial press release(s) announcing this Agreement or other public disclosure approved by both Parties, either Party shall be free to
disclose, without the other Party’s prior written consent, the existence of this Agreement, the identity of the other Party and those terms of the Agreement which have already been publicly disclosed in accordance herewith. 
 8.7 Specific Performance. Each Party acknowledges and agrees that disclosure or distribution of the Confidential Information or use
of the Confidential Information of the other Party contrary to the terms of this Agreement may cause irreparable harm to the disclosing Party for which damages at law may not provide an adequate remedy and agrees that the provisions of this Article
may be specifically enforced without regard to the provisions of Article XII and are in addition to any and all other remedies available at law or in equity. 
 8.8 Issuance and Maintenance of ARCA Patent. ARCA agrees that it shall use commercially reasonable efforts to prosecute all patent applications within the ARCA Patent and use commercially
reasonable efforts to obtain valid, issued patents based on such applications. During the term of this Agreement, ARCA shall submit all filings, make all payments, and take all other actions reasonably necessary to maintain the ARCA Patent, once
issued, as valid, in force and in good standing with the U.S. Patent and Trademark Office (at its own expense). 
  

 Development, Commercialization and Licensing Agreement-Confidential-Page 21 

 8.9 Enforcement of Rights to ARCA Technology and Trademark. During the term of this
Agreement, ARCA agrees that it shall, at its own expense, use commercially reasonable efforts to .enforce its rights with respect to any material infringement or misappropriation in the Territory by a Third Party of any of the ARCA Technology or the
Trademark. Without limiting the foregoing, in the event a Third Party is infringing on the ARCA Technology or Trademark by making, performing, using, selling or importing Diagnostic Tests and ARCA is unsuccessful in persuading such infringer to
desist and fails to have initiated and diligently pursue an infringement suit within a reasonable time (not to exceed [    *    ] months) after ARCA first becomes aware of the basis for such suit, ARCA shall
grant LabCorp and its Affiliates the right to file suit on its behalf to enforce its rights with respect to the Field only, and ARCA agrees to cooperate and provide reasonable assistance to LabCorp and its Affiliates in connection with such suit.
LabCorp and its Affiliates shall have the right to any recovery or damages obtained as a result of a suit brought by LabCorp and its Affiliates (whether by settlement, judgment or otherwise). 
 ARTICLE IX 
 REPRESENTATIONS, WARRANTIES AND
COVENANTS 
 9.1 Mutual Representations, Warranties and Covenants. Each Party hereby represents, warrants and
covenants to the other Parry as follows: 
 (a) Such Party: (i) is a corporation duly organized, validly existing
and in good standing under the laws of the jurisdiction in which it is incorporated or organized; (ii) has the corporate power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder; and
(iii) has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. 
 (b) This Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms, and the
execution, delivery and performance of this Agreement by such Party does not conflict with any material agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any law or regulation of any
court, governmental body or administrative or other agency having jurisdiction over it. 
 (c) All material consents,
approvals and authorizations of all governmental authorities and other persons required to be obtained by such Party in connection with the execution and delivery and performance of this Agreement have been and shall be obtained. 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 22 

 9.2 LabCorp Representations, Warranties and Covenants. LabCorp (and each of its
Affiliates acting under this Agreement, to the extent applicable) hereby represents, warrants and covenants to ARCA as follows: 
 (a) LabCorp’s obligations and responsibilities under this Agreement will be performed in a competent manner in conformance with the standard of care usually and reasonably expected in the performance of such activities, and in
compliance with applicable federal, state and local laws, rules and regulations, as interpreted and enforced by Regulatory Authorities. [    *    ] Notwithstanding anything in this Agreement, LabCorp shall not
have any obligation or responsibility to perform any activity that is contrary to applicable federal, state and local laws, rules and regulations, as interpreted and enforced by Regulatory Authorities, including the guidance of Regulatory
Authorities with respect to the legal marketing of the Commercial Platform. 
 (b) Neither LabCorp nor any of its
employees or agents rendering services pursuant to this Agreement is under investigation by any Regulatory Authority, including the FDA, for activities that could form the basis of a debarment action or is presently debarred pursuant to the Generic
Drug Enforcement Act of 1992, 21 U.S.C. § 335a, or any other similar law of any Regulatory Authority in the Territory. LabCorp shall notify ARCA and the Diagnostics Committee immediately upon any inquiry concerning or the commencement of
any such proceeding involving LabCorp or any person or entity related to or involved in LabCorp’s performance of its obligations under this Agreement. 
 (c) If any Regulatory Authority conducts or gives notice to LabCorp of its intent with respect to any activities under this Agreement to conduct an inspection at any LabCorp facility where the
Homebrew Assays or IVD Products are performed or the IVD Kits are manufactured or used or take any other regulatory action related to any activities under this Agreement, or if LabCorp becomes aware of any such governmental inspection or other
regulatory activity, LabCorp shall promptly give ARCA and the Diagnostics Committee notice thereof, including all information pertaining to any such inspections or actions, unless and only to the extent restricted by the governmental or Regulatory
Authority or applicable law. 
 (d) LabCorp’s personnel and consultants have, and shall have, all training,
licenses, approvals, certifications, immunizations, equipment and information necessary for safely and properly performing the obligations under this Agreement, and it will ensure that all such training, licenses, approvals, certifications,
immunizations, equipment and information are properly maintained throughout the conduct of LabCorp’s activities under this Agreement. 
 (e) LabCorp is and will remain (and shall use reasonable efforts to ensure any Third Party retained by LabCorp as permitted by this Agreement is and will remain) in substantial compliance with
regulatory and legal requirements, as interpreted and enforced by Regulatory Authorities, which may be necessary for Regulatory Approval of the Commercial Platform. 
 (f) Neither LabCorp nor any of its personnel or any Third Party engaged to perform any activities in the development of the Commercial Platform have been involved in an investigation or in research
that was terminated, as the term “termination” is used in 21 C.F.R. § 812.3(8), nor have they been subjected to any restrictions or sanctions related to allegations of research or professional misconduct. 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 23 

 (g) In the event LabCorp elects to obtain a license directly from CardioDx to the
ARCA Technology as provided in Section 2.1, during the term of this Agreement, LabCorp covenants that it shall (i) satisfy all of its obligations under the terms of any agreement with CardioDx pursuant to which it obtains such
license (the “LabCorp CardioDx Agreement”), to the extent such obligations relate to or affect LabCorp’s rights in the Field; (ii) not terminate, amend or assign, nor by act or omission permit the termination, amendment or
assignment of, the LabCorp CardioDx Agreement (to the extent it relates to or affects LabCorp’s rights in the Field) in a manner that would adversely affect LabCorp’s ability to perform its obligations hereunder without the prior written
consent of ARCA; and (iii) provide ARCA with prompt notice of any claim of a material breach under the LabCorp CardioDx Agreement made by either CardioDx or LabCorp, to the extent it relates to or could affect LabCorp’s rights in the
Field. 
 (h) Each of the entities listed on Exhibit A hereto is a wholly-owned subsidiary of LabCorp. 

9.3 ARCA Representations, Warranties and Covenants. ARCA hereby represents, warrants and covenants to LabCorp as follows:

 (a) ARCA (i) has the necessary rights to license the ARCA Technology and Trademark and sublicense the rights
under the CardioDx Agreement to LabCorp pursuant to the terms of this Agreement; and (ii) has not granted to any Third Party any rights that conflict with or materially and adversely affect the rights granted by ARCA hereunder. 
 (b) To ARCA’s knowledge, the exercise of the licenses granted to LabCorp under the ARCA Technology and Trademark and the
CardioDx Agreement, including without limitation the development, manufacture, use, sale and import of the Diagnostic Tests, do not interfere with or infringe any intellectual property rights owned or possessed by any Third Party. 
 (c) ARCA’s obligations and responsibilities under this Agreement will be performed in a competent manner in conformance with the
standard of care usually and reasonably expected in the performance of such activities, and in compliance with all applicable, federal, state and local laws, rules and regulations, as interpreted and enforced by Regulatory Authorities.
Notwithstanding anything in this Agreement, ARCA shall not have any obligation or responsibility to perform any activity that is contrary to applicable federal, state and local laws, rules and regulations, as interpreted and enforced by Regulatory
Authorities, including the guidance of Regulatory Authorities with respect to the legal marketing of the Commercial Platform. 
 (d) ARCA provided a ROFN Notice (as defined in Section 3.1(b) of the CardioDx Agreement) to CardioDx, CardioDx provided a Notice of Interest (as defined Section 3.1(c) of the CardioDx Agreement), and ARCA and
CardioDx did not enter into a letter of intent or definitive agreement within the Negotiation Period (as defined Section 3.1(c) of the CardioDx Agreement), which expired prior to the Effective Date of this Agreement. Accordingly, the
Right of First Negotiation (as defined in Section 3.1(a) of the CardioDx Agreement) has terminated and CardioDx has no further rights under Section 3.1 of the CardioDx Agreement. 
  

 Development, Commercialization and Licensing Agreement-Confidential-Page 24 

 (e) ARCA has delivered to LabCorp a true and complete copy of the CardioDx Agreement
and the UC Licenses, including any and all amendments, side letters, or other modifications thereto, as in effect as of the Effective Date. The CardioDx Agreement and, to ARCA’s knowledge, the UC Licenses, are presently valid and in full force
and effect. ARCA has duly and punctually performed all of its obligations under the CardioDx Agreement. During the term of this Agreement, ARCA further covenants that it shall (i) satisfy all of its obligations under the terms of the CardioDx
Agreement (except for the obligation of payment of royalties thereunder assumed by LabCorp pursuant to Section 7.1 hereof); (ii) not terminate, amend or assign, nor by act or omission permit the termination, amendment or assignment
of, the CardioDx Agreement in a manner that would adversely affect LabCorp’s rights hereunder without the prior written consent of LabCorp; and (iii) provide LabCorp with prompt notice of any claim of a material breach under the CardioDx
Agreement made by either CardioDx or ARCA. 
 ARTICLE X 
 TERM AND TERMINATION 
 10.1 Term. This
Agreement shall commence as of the Effective Date and, unless sooner terminated as provided herein, shall continue in effect until the ten (10) year anniversary of the Effective Date. 
 10.2 Termination by LabCorp. This Agreement may be terminated by LabCorp in whole or in part as provided below: 
 (a) At any time during the term of this Agreement if ARCA materially breaches this Agreement, which breach is not cured within sixty
(60) days of written notice thereof from LabCorp. 
 (b) At any time during the term of this Agreement upon written
notice if ARCA becomes and remains subject to a Bankruptcy Event. 
 (c) At any time during the term of this Agreement
upon written notice given by LabCorp at least ninety (90) days prior to the effective date of such termination in the event that a claim is made by a Third Party that the performance or sale of the Diagnostic Tests infringes or otherwise
violates such Third Party’s intellectual property rights, unless ARCA obtains a license from such Third Party (at ARCA’s own cost and expense) during such ninety (90) day period that would permit LabCorp’s performance and sale of
the Diagnostic Tests, or agrees to indemnify LabCorp, to LabCorp’s reasonable satisfaction, for any liability arising from such claim. 
 (d) At any time during the term of this Agreement upon written notice given by LabCorp at least sixty (60) days prior to the effective date of such termination in the event a Regulatory
Authority advises either Party in writing, or issues any written decision, pronouncement, or other communication, including but not limited to letters, emails, website information, final guidance documents, or final rulemaking, either to the
Parties, to the public or to Third Parties, which provides a reasonable basis for concluding that LabCorp’s use of the Commercial Platform as contemplated by this Agreement, in whole or in part, may be in violation of applicable law,

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 25 

 (e) At any time during the term of this Agreement for any reason upon written notice
given by LabCorp at least [    *    ] months prior to the effective date of such termination. 
 (f) At any time upon thirty (30) days prior written notice in the event the Parties are unable to agree upon the initial Commercial Plan or initial Regulatory Plan. 
 (g) At any time immediately upon written notice in the event of a Change of Control with respect to ARCA which results in one or more
national or regional commercial reference clinical laboratories (other than LabCorp) directly or indirectly holding a majority of the outstanding voting securities of ARCA or the power to direct or cause the direction of the management and policies
of ARCA. 
 (h) In the event that Regulatory Approval for the Commercial Platform or the Drug Product is not received
within [    *    ] months of the date hereof. 
 (i) At any time upon thirty
(30) days prior written notice in the event ARCA is unable to obtain the approval of CardioDx for all of the Third Parties listed on Exhibit B to be deemed Permitted Sublicensees within the timeframes provided in Section 2.6;
provided, however, that any notice of termination by LabCorp under this Section 10.2(i) must be given by LabCorp within ninety (90) days after the date CardioDx notifies LabCorp in writing that ARCA could not obtain such
approval from CardioDx, or such right of termination shall be deemed waived. 
 (j) At any time upon thirty
(30) days prior written notice in the event ARCA is unable to obtain the approval of CardioDx for LabCorp’s Affiliates (including without limitation wholly-owned Affiliates that LabCorp may acquire in the future) to be included within the
sublicense granted under Section 2.1, within the timeframes provided in Section 2.8; provided, however, that any notice of termination by LabCorp under this Section 10.2(j) must be given by LabCorp within
ninety (90) days after the date CardioDx notifies LabCorp in writing that ARCA could not obtain such approval from CardioDx, or such right of termination shall be deemed waived. 
 10.3 Termination by ARCA. This Agreement may be terminated by ARCA in whole or in part as provided below: 
 (a) At any time during the term of this Agreement if LabCorp materially breaches this Agreement, which breach is not cured within
sixty (60) days of written notice thereof from ARCA. 
 (b) At any time during the term of this Agreement upon
written notice if LabCorp becomes and remains subject to a Bankruptcy Event. 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 26 

 (c) In the event that Regulatory Approval for either the Drug Product or the
Commercial Platform is not received within [    *    ] months of the Effective Date. 
 (d) [    *    ] 
 (e) At any time during the term of this
Agreement upon written notice given [    *    ] at least ninety (90) days prior to the effective date of such termination in the event that a claim is made by a Third Party that the
[    *    ], unless [    *    ] pursuant to the terms of Section 11.3 for any liability arising from such claim. 
 (f) At any time during the term of this Agreement upon written notice given by [    *    ] at
least [    *    ] if [    *    ] in connection with [    *    ]. 
 (g) At any time upon thirty (30) days prior written notice in the event the Parties are unable to agree upon the initial
Commercial Plan or initial Regulatory Plan. 
 (h) At any time immediately upon written notice in the event of a Change
of Control with respect to LabCorp which results in a competitor of ARCA directly or indirectly holding a majority of the outstanding voting securities of LabCorp or the power to direct or cause the direction of the management and policies of
Labcorp. 
 10.4 Automatic or Mutual Termination. 
 (a) The Agreement shall automatically terminate in the event the CardioDx Agreement terminates or expires for any reason and if ARCA
is unsuccessful in licensing the necessary rights from UC, unless (i) LabCorp has made arrangements to secure the rights under the CardioDx Agreement directly from CardioDx as contemplated by Section 2.1 or otherwise outside of this
Agreement, or (ii) LabCorp determines that the rights under the CardioDx Agreement are not necessary in order for LabCorp to perform its obligations under this Agreement. 
 (b) Either Party may terminate this Agreement upon sixty (60) days’ notice by either Party if the Parties are unable to
agree upon amendments to this Agreement following ARCA’s conversion of the licenses granted under this Agreement to non-exclusive licenses pursuant to Section 10.5. 
 10.5 Loss of Exclusivity. In the event LabCorp materially breaches this Agreement, including a failure to satisfy any milestones,
[    *    ] requirements, or other performance standards expressly stated to be a condition of exclusivity in any Commercialization Plan, and any such failure is not cured within sixty (60) days after
written notice thereof from ARCA, ARCA may, in its sole discretion and upon written notice to LabCorp, elect to terminate its obligations under Section 2.5 and to convert the sublicense granted under Section 2.1 to a
nonexclusive sublicense and the license granted under Section 2.2 to a nonexclusive license. Such termination of the obligations under Section 2.5 and conversion to a nonexclusive 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 27 

 sublicense and nonexclusive license, as applicable, shall be effective immediately following expiration of
such sixty (60)-day period or at some later time, as determined by ARCA in its sole discretion, as may be necessary in order to obtain a Third Party supplier of the Diagnostic Tests and Commercial Platform. Upon such termination, the Parties shall
negotiate appropriate modifications to the provisions of this Agreement or any plans which may be impacted by the conversion of the licenses from exclusive to non-exclusive (including without limitation modifications to any such milestone,
requirement or standard LabCorp failed to satisfy, as well as other milestones, requirements or standards that may be impacted by the non-exclusive nature of the license and adjustments to the royalties or other payments under Article VII
based on the non-exclusive nature of the licenses). The exercise by ARCA of its rights under this Section 10.5 shall not be deemed a waiver of any of ARCA’s other rights under this Agreement, including pursuant to Sections
6.2 and 10.3, upon the occurrence of any of the events specified in this Section. 
 10.6 Effect of Termination.

 (a) Upon termination of this Agreement for any reason, each Party shall cooperate with the other Party for an
orderly wind-down of the services provided by LabCorp hereunder and all rights granted by ARCA to LabCorp under this Agreement shall revert back to ARCA. Any termination of this Agreement as provided herein shall not be an exclusive remedy but shall
be in addition to any remedies whatsoever that may be available to the terminating party. 
 (b) Upon any termination or
expiration of this Agreement, each Party shall return to the other Party all Information of the other Party in such Party’s Control, except that one copy may be retained solely for archival purposes. 
 (c) Upon termination of this Agreement by LabCorp under Section 10.2 (e), or by ARCA
[    *    ] at any time prior to sixty (60) days after the effective date of termination, [    *    ], subject to the terms and conditions related thereto. Upon
termination of this Agreement by [    *    ], subject to the terms and conditions related thereto; provided, however, that [    *    ]. 
 10.7 Surviving Rights. Except as expressly modified above in this Article X, the obligations and rights of the Parties under
Articles I, VII (as it relates to sales that occurred during the term of this Agreement), VIII, XI, XII and XIII, and Sections 4.6, 10.6, and 10.7 of this Agreement will survive termination or expiration of this
Agreement. 
 10.8 Accrued Rights, Surviving Obligations. Unless explicitly provided otherwise in this Agreement,
termination, relinquishment, or expiration of the Agreement for any reason shall be without prejudice to any rights which shall have accrued to the benefit to either Party prior to such termination, relinquishment, or expiration, including damages
arising from any breach hereunder. Such termination, relinquishment, or expiration shall not relieve any Party from obligations which are expressly indicated to survive termination or expiration of the Agreement. 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 28 

 ARTICLE XI 
 INDEMNIFICATION; INSURANCE 
 11.1 LabCorp
Indemnification. LabCorp hereby agrees to save, defend, and hold ARCA and its agents and employees harmless from and against any and all suits, claims, actions, demands, liabilities, expenses and/or loss, including reasonable legal expense and
attorneys’ fees (“Losses”) resulting from: [    *    ]. 
 11.2 ARCA Indemnification. ARCA hereby agrees to save, defend, and hold LabCorp and its agents and employees harmless from and against any and all Losses resulting from: (i) breach by ARCA or its Affiliates in the performance of
its obligations under this Agreement (except in the case where exclusive remedies are specified for such breach); (ii) negligence or willful misconduct on the part of ARCA or its Affiliates; (iii) the manufacture, use, handling, storage,
sale, distribution, or other disposition of the Drug Product by ARCA, its Affiliates, agents, or sublicensees; and (iv) claims that the development, manufacture, performance, use, sale or importation of the Diagnostic Tests interferes with or
infringes any intellectual property rights owned or possessed by any Third Party, but only to the extent LabCorp is not indemnified against such claims under the LabCorp CardioDx Agreement (if applicable), and only to the extent such claims are
based on intellectual property rights licensed hereunder. 
 11.3 Indemnification Procedures. A Party (the
“Indemnitee”) which intends to claim indemnification under this Section shall notify the other Party (the “Indemnitor”) within a reasonable time in writing of any action, claim or liability in respect of which the
Indemnitee believes it is entitled to claim indemnification, provided that the failure to give timely notice to the Indemnitor shall not release the Indemnitor from any liability to the Indemnitee to the extent the Indemnitor is not prejudiced
thereby. The Indemnitor shall have the right, by notice to the Indemnitee, to assume the defense of any such action or claim after the Indemnitor’s receipt of notice of any action or claim with counsel of the Indemnitor’s choice and at the
sole cost of the Indemnitor. If the Indemnitor does not so assume the defense of such third party claim, the Indemnitee may assume such defense with reasonable counsel of its choice and at the sole cost of the Indemnitor. If the Indemnitor so
assumes such defense, the Indemnitee may participate therein through counsel of its choice, but at the sole cost of the Indemnitee. The Party not assuming the defense of any such claim shall render all reasonable assistance to the Party assuming
such defense upon request, and all reasonable out-of-pocket costs of such assistance shall be for the account of the Indemnitor. No such claim shall be settled other than by the Party defending the same, and then only with the consent of the other
Party which shall not be unreasonably withheld; provided that the Indemnitee shall have no obligation to consent to any settlement of any such action or claim which imposes on the Indemnitee any liability or obligation which cannot be assumed
and performed in full by the Indemnitor, and the Indemnitee shall have no right to withhold its consent to any settlement of any such action or claim if the settlement involves only the payment of money by the Indemnitor or its insurer. 

 
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 29 

 11.4 Limitation of Liability. In no event will either party be liable to the other
party for any indirect, special, incidental, consequential, or punitive damages incurred by the other party and arising out of or in connection with this Agreement. 
 11.5 Insurance. Each Party will during the term of this Agreement carry insurance policies in such amounts and providing such coverage as is reasonable and customary for commercial entities
providing services like those being rendered by such party under this Agreement. 
 ARTICLE XII 
 DISPUTE RESOLUTION 
 12.1 Disputes. 
 (a) The Parties recognize that disputes may arise from time to time respecting this
Agreement and the rights and obligations of the Parties under this Agreement, and desire to establish the procedures in this Article to facilitate their resolution in an expedient and commercially reasonable manner by mutual cooperation and without
resort to litigation. 
 (b) Except as otherwise provided in this Agreement or agreed by the Parties, disputes within the
Diagnostics Committee will be resolved as recited in this Article. If the Diagnostics Committee is unable to resolve such a dispute within thirty (30) days, either Party, by written notice to the other, may have such dispute referred to their
respective executive officers designated below or their successors, for attempted resolution by good faith negotiations: 
 For LabCorp:             Executive Vice President of LabCorp 
 For ARCA:                 Chief Executive Officer of ARCA 
 In the event the designated executive officers are not able to resolve any unresolved dispute within the Diagnostics Committee within thirty
(30) days after written notice by either Party referring the matter to them as provided herein, either Party may by written notice to the other commence the process set forth in Section 12.2 below. 
 (c) Except as otherwise provided in this Agreement or agreed by the Parties, any other unresolved dispute regarding the
interpretation of or the Parties’ respective rights and obligations under this Agreement shall first be referred to the Diagnostics Committee, then to the two executives, as aforesaid, then to the Arbitration process set forth in
Section 12.2 below. 
 12.2 Arbitration by Expert Panel. Except to the extent otherwise provided in this
Agreement or by agreement of the Parties, any dispute, controversy, or claim arising out of or relating to the validity, construction, enforceability, or performance of this Agreement, including any dispute relating to alleged breach or to
termination of this Agreement, that remains unresolved after going through the process set forth in Section 12.1 above shall be subject to the following alternative dispute resolution process (“Arbitration”): 

(a) The Party invoking the Arbitration shall give written notice (“Arbitration Notice”) thereof to the other
Party, setting forth in reasonable detail the issues to be resolved. As soon as possible but in any event within fifteen (15) days following such delivery of such notice, each Party will appoint one neutral expert in the subject matter of the
issues in dispute to serve as an arbitrator, and these two arbitrators will as soon as possible but in any event within ten (10) days following delivery of such notice appoint a third similarly qualified neutral expert to serve as the third
arbitrator (such three arbitrators, the “Panel”). 
  

 Development, Commercialization and Licensing Agreement-Confidential-Page 30 

 (b) The members of the Panel shall be “neutral” in that they are not nor
have they been within the previous five years employees or paid consultants of either Party, nor have any other extended familial, close social or other material relation to either Party, and “expert” in that they are highly qualified in
the field of the issues under dispute. 
 (c) The Panel shall hold a hearing (the “Hearing”) on the
merits of the dispute as soon as possible but in no event more than sixty (60) days following delivery of the Arbitration Notice. Each Party may if it has time submit one written brief, along with reasonable supporting materials, setting forth
the issues of the dispute and a specific suggested resolution requested by such Party, which will be submitted simultaneously to the Panel and the other Party. The Hearing shall take place over a period of no more than two full consecutive business
(or if agreeable to the Panel, calendar) days following a reasonable procedure adopted by the Panel for presentations, questions and answers, and discussions. Within ten (10) days following the Hearing, the Panel will present its decision
(“Decision”) in writing, acting with the concurrence of at least two Arbitrators, which will choose the resolution requested by one of the Parties (or if the Panel desires, offers a resolution other than either resolution requested
by the Parties), together with a statement in reasonable detail of the reasons therefor. 
 12.3 Disputes About the
Arbitration. All disputes relating to the proper execution of the Arbitration (including, without limitation, failure of a Party to comply with the timing or other requirements of the arbitration or the fairness or appropriateness of an
arbitrator) shall be finally settled in a binding manner on both Parties by a retired federal court judge or, if not available, some other experienced professional adjudicator or arbitrator appointed by the President or other senior executive of the
American Arbitration Association (such retired judge, adjudicator, or arbitrator, a “Referee”) in an expedited hearing not to exceed one full business day (“Referee Hearing”) within fifteen (15) days of
invocation in writing by either Party. 
 12.4 Fees and Costs of the Arbitration. Each Party shall bear its own costs of
the Arbitration (including any Referee Hearing), but will share equally for payment of the fees and costs of the Panel and of any Referee. 
 12.5 Waivers or Alterations to the Dispute Resolution Procedure. The Parties may mutually agree in writing to waive or alter aspects of these Arbitration provisions in any Arbitration. The time
limits provided in this Article XII may be waived or altered in case of serious hardship or inconvenience on the part of any Arbitrator or Referee, provided that any such waiver or alteration be minimized to the extent possible in accordance
with the intent of the Parties at the time of the execution and delivery of this Agreement that the Arbitration procedure yield expedited resolutions. 
  

 Development, Commercialization and Licensing Agreement-Confidential-Page 31 

 12.6 Arbitration Confidentiality. All aspects of the Arbitration and any Referee
Hearing, including the Decision, shall be confidential, and all participants including the Panel and the Referee shall be bound by judicially enforceable obligations of strict confidentiality except to the extent the Parties agree in writing to
waive in whole or part such confidentiality. 
 12.7 Survival. Any duty to arbitrate under this Agreement shall remain in
effect and enforceable after termination of this Agreement for any reason. 
 12.8 Jurisdiction. For the purposes of this
Article XII, the Parties agree to accept the jurisdiction of the Federal District Court Delaware, for the purposes of enforcing Decisions agreed to by the Parties and for enforcing the agreements reflected in this Article. 
 12.9 Exceptions. Notwithstanding the provisions of this Article XII, proceedings may be brought in any court of competent
jurisdiction for the limited purpose of: (i) obtaining preliminary or permanent injunctive relief, (ii) recovering possession of property (such as replevin, claim and delivery, attachment or the like), or (iii) impleading, joining or
adding another party as a third-party defendant in any legal action brought by a Third Party. 
 ARTICLE XIII 

MISCELLANEOUS 
 13.1 Assignment. 
 (a) Neither Party may assign its rights or obligations under this Agreement without
the prior written consent of the other Party; provided, however, that upon prior written notice to the other Party, either Party may assign any of its rights or obligations under this Agreement to any Affiliates of such Party; and
provided, further, that ARCA may assign this Agreement to an entity (other than a national or regional commercial reference clinical laboratory) that acquires all or substantially all of the business or assets of ARCA to which this
Agreement pertains (including by way of merger, consolidation, reorganization, acquisition, sale or otherwise) and such entity agrees to be bound by the terms and conditions of this Agreement. In any assignment of this Agreement to an Affiliate of a
Party, the assigning Party shall remain responsible to be guarantor of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. 
 (b) Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns
of the Parties. Any assignment not in accordance with this Agreement shall be null and void and of no effect. 
 13.2 Costs
and Expenses. Except as otherwise provided in this Agreement, or as agreed to from time to time by the Parties, each Party shall bear all of its own costs and expenses incurred in connection with performing its respective obligations under this
Agreement. 
 13.3 Retained Rights. Nothing this Agreement shall limit in any respect the right of either Party to
conduct research and development with respect to and market products outside the Field using such Party’s technology. 
  

 Development, Commercialization and Licensing Agreement-Confidential-Page 32 

 13.4 Force Majeure. Neither Party shall lose any rights hereunder or be liable to the
other Party for damages or losses on account of failure of performance by the defaulting Party if the failure is occasioned by government action, war, fire, explosion, flood, strike, lockout, embargo, act of God, or other cause beyond the reasonable
control of the defaulting Party, provided that the Party claiming force majeure has exerted commercially reasonable efforts to avoid or remedy such force majeure, provided that in no event shall a Party be required to settle any labor dispute or
disturbance. 
 13.5 Further Actions. Each Party agrees to execute, acknowledge, and deliver such further instruments,
and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 13.6 No Trademark Rights. Except as otherwise provided herein, no right, express or implied, is granted by the Agreement to use in any manner the name “LabCorp,” “ARCA” or any other trade name or trademark of the
other Party or its Affiliates in connection with the performance of this Agreement. 
 13.7 Notices. All notices
hereunder shall be in writing and shall be deemed given when delivered personally, the same business day as sent by facsimile transmission (receipt verified), three business days after being mailed by registered or certified mail (return receipt
requested), postage prepaid, or the next business day after being sent by express courier service (next business day delivery provided), to the Parties at the following addresses (or at such other address for a parry as shall be specified by like
notice. 
  

			
	If to ARCA, addressed to:	  	ARCA Discovery, Inc.
		  	1200 Seventeenth Street, Suite 620
		  	Denver, Colorado 80202
		  	Attention: Chief Executive Officer
		  	Telephone: (303) 893-1606
		  	Facsimile: (303) 825-0883
		
	If to LabCorp, addressed to:	  	Laboratory Corporation of America Holdings
		  	430 South Spring Street
		  	Burlington, North Carolina 27215
		  	Attention: Law Department
		  	Telephone: (336) 436-8069
		  	Facsimile: (336) 226-3835
		
	With a copy to:	  	Parker, Poe, Adams & Bernstein L.L.P.
		  	P.O. Box 389
		  	150 Fayetteville Street, Suite 1400
		  	Raleigh, North Carolina 27602
		  	Telephone: (919) 828-0564
		  	Facsimile: (919) 834-4564
		  	Attn: Frank E. Silber, Esq.

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 33 

 13.8 Waiver. Except as specifically provided for herein, the waiver from time to time
by either of the Parties of any of their rights or their failure to exercise any remedy shall not operate or be construed as a continuing waiver of same or of any other of such Party’s rights or remedies provided in this Agreement.

 13.9 Severability. If any term, covenant, or condition of this Agreement or the application thereof to any Party or
circumstance shall, to any extent, be held to be invalid or unenforceable, then (i) the remainder of this Agreement, or the application of such term, covenant, or condition to Parties or circumstances other than those as to which it is held
invalid or unenforceable, shall not be affected thereby and each term, covenant, or condition of this Agreement shall be valid and be enforced to the fullest extent permitted by law; and (ii) the Parties hereto covenant and agree to renegotiate
any such term, covenant, or application thereof in good faith in order to provide a reasonably acceptable alternative to the term, covenant, or condition of this Agreement or the application thereof that is invalid or unenforceable, it being the
intent of the Parties that the basic purposes of this Agreement are to be effectuated. 
 13.10 Ambiguities. Ambiguities,
if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision. 
 13.11 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 13.12 Days. Unless otherwise explicitly stated herein, references in this Agreement to a number of days shall mean
calendar days. As used in this Agreement, “business day” refers to any day other than a Saturday, Sunday, and any day on which banking institutions in the State of Delaware are either required or permitted to close pursuant to applicable
law, rule, regulation or executive order. 
 13.13 Governing Law. This Agreement, and any dispute or controversy arising
out of or relating thereto, shall in all respects be governed by and construed according to the laws of the State of Delaware (excluding its conflicts of law principles). 
 13.14 Entire Agreement. This Agreement sets forth all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto and supersedes and
terminates all prior agreements and understandings between the Parties. There are no covenants, promises, agreements, warranties, representations, conditions, or understandings, either oral or written, between the Parties other than as set forth
herein and therein. No subsequent alteration, amendment, change of addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties. 
 IN WITNESS WHEREOF, the Parties hereto have caused this Development, Commercialization and Licensing Agreement to be executed by their duly
authorized representatives as of the day and year first above written. 
  

 Development, Commercialization and Licensing Agreement-Confidential-Page 34 

			
	ARCA DISCOVERY, INC., a Delaware corporation
		
	By:	 	 /s/ Richard B. Brewer

		 	Richard B. Brewer
		 	Chief Executive Officer
	
	LABORATORY CORPORATION OF
AMERICA HOLDINGS, a Delaware corporation
		
	By:	 	 /s/ Bradford T. Smith

	Name:	 	Bradford T. Smith
	Title:	 	E.V.P.

  

 Development, Commercialization and Licensing Agreement-Confidential-Page 35 

 EXHIBIT A 
 WHOLLY-OWNED SUBSIDIARIES OF LABCORP 
 Laboratory Corporation of America 
 LabCorp BVBA

 ViroMed Laboratories Inc. 
 Path Lab
Holdings, Inc. 
 National Genetic Institute 
 Center for Genetic Services, Inc. 
 Dianon Systems, Inc. 
 US Pathology Labs, Inc. 
 Esoterix, Inc. 
  

 Development, Commercialization and Licensing Agreement-Confidential-Exhibits 

 EXHIBIT B 
 PERMITTED SUBLICENSEES 
 [    *    ] 
  
  

	[*]	Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities and Exchange Act of 1934, as amended. 

  

 Development, Commercialization and Licensing Agreement-Confidential-ExhibitsAmendment Number 3 to Research Collaboration and License Agreement

					
		 	 Confidential Materials omitted and filed separately with the
 Securities and Exchange Commission. Astersisks denote
omissions.
	 	Exhibit 10.1

 AMENDMENT NO. 3 TO 
 RESEARCH COLLABORATION AND LICENSE AGREEMENT 
 This
Amendment No. 3 to the Research Collaboration and License Agreement (the “Amendment #3”), effective as of September 2, 2009, modifies certain provisions of the Research Collaboration and License Agreement, entered into as of
November 24, 2004, as amended by Amendment No. 1 dated March 26, 2007, and Amendment No. 2 dated January 15, 2009, (as previously amended, the “Agreement”) between Achillion Pharmaceuticals, Inc., 300 George
Street, New Haven, Connecticut 06511 (“Achillion”), and Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (“Gilead”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned
to such terms in the Agreement. 
 WHEREAS, the Parties arrived at different opinions on the appropriate further
progression of ACH-1095 (defined below), the current Lead Compound; 
 WHEREAS, the Parties have decided, among
other things, to permit Achillion to clinically Develop ACH-1095 at its own cost, and to make all decisions with respect thereto, subject to Achillion granting Gilead options to again participate in the Development and commercialization of ACH-1095,
such options to be exercised, if at all, on or before the end of the Interim Period (defined below); 
 WHEREAS,
the Parties also desire to amend certain other provisions of the Agreement; 
 NOW, THEREFORE, in
accordance with Section 12.12 of the Agreement, Gilead and Achillion hereby modify the Agreement as follows: 
 1. New
Definitions. Section 1 of the Agreement is amended by adding the following definitions: 
 ““ACH-1095” means the Compound known as ACH-1095 (also known as GS-9525).” 
 ““Amendment #3 Effective Date” means September 2, 2009.” 
 ““Interim
Period” means the period beginning on the Amendment #3 Effective Date and continuing until the earliest of (a) Gilead’s exercise of its opt-in right pursuant to Section 2A.2, (b) forty-five (45) days after
Gilead’s receipt of a POC Notice, (c) forty-five (45) days after Gilead’s receipt of a POC Failure Notice.” 
 ““Other Compounds” means Compounds other than ACH-1095.” 
 2. Further Amendment of
Exhibit 1.2. Exhibit 1.2, as previously amended, is hereby amended by inserting the following sentence at the end thereof: 
 “Notwithstanding the foregoing, Compounds shall exclude compounds that have not been conceived, made or identified by either Party prior to the Amendment #3 Effective Date.” 
  

 1 

 3. Amendment of Exhibit 1.3. Exhibit 1.3 is hereby restated in its entirety to read
as follows: 
 “ “Proof of Concept” means: 
 Demonstration of [**]. 
 A clinical study of suitable design as described in the prior paragraph
[**] from the contract research organization(s) implementing the study.” 
 4. Amendment of Exhibit 2.2. The section
of Exhibit 2.2 entitled “Phase 1b Proof-of-Concept Study in HCV Infected Patients” is hereby restated in its entirety to read as follows: 
 “Phase 1b [**] 
 This study will [**] into longer-term studies. This study will [**]. This study will [**],
will be agreed to by the Research Committee. [**], the Parties will agree [**] 
 5. Interim Period Activities.
The following provisions are added as new Section 2A of the Agreement, immediately before Section 3 of the Agreement: 
 “2A
INTERIM PERIOD ACTIVITIES. 
 2A.1 Interim Period
Activities. The Parties agree that, notwithstanding anything to the contrary in the Agreement, the following rights and obligations shall apply during the Interim Period: 
 (a) Gilead shall not conduct research on, or Develop, ACH-1095; 
 (b) the Research Committee shall have no authority with respect to ACH-1095; 
 (c) Achillion may conduct, and have sole decision-making authority with respect to, any research and Development activities with respect to
ACH-1095, in Achillion’s discretion and at Achillion’s expense, without input from the Research Committee or Gilead; provided, however, that Achillion will provide Gilead with regular updates in writing no less than once per calendar
quarter summarizing Achillion’s research and Development activities with respect to ACH-1095; 
 (d) Achillion shall hold a
pre-IND consultation with the FDA to determine a possible path to Develop ACH-1095 (the “FDA Meeting”); 
 (e)
Achillion shall provide Gilead with copies of all material correspondence sent to and received from the FDA with respect to ACH-1095; 
  

 2 

 (f) Gilead shall not exercise any rights under the license granted to Gilead pursuant to
Section 5.1 with respect to ACH-1095 and any Licensed Product containing ACH-1095, and Gilead shall not sublicense any rights thereunder, nor shall Gilead grant any rights to, or enter any agreement with, any Third Party for the sale of any
Licensed Product containing ACH-1095; 
 (g) the provisions of Section 9.2(a)(ii) shall apply with respect to any Patent
Costs for Achillion Patents; 
 (h) the diligence obligations set forth in Section 9.2(c) shall only apply to Achillion
Patents relating to ACH-1095 or a Licensed Product containing ACH-1095, provided, however, that Achillion’s rights set forth in Section 9.2(b) with respect to Achillion Patents that are abandoned by Gilead shall remain in full force and
effect with respect to any Achillion Patent; 
 (i) the provisions of Section 2.4(c) shall remain in effect with respect to
any Research Costs incurred with respect to ACH-1095 on or before the Amendment #3 Effective Date; 
 (j) Gilead shall not be
responsible for Research Costs incurred on or after the Amendment #3 Effective Date unless Gilead (i) provides written notice of its intention to do so, or (ii) exercises its opt-in right pursuant to Section 2A.2(a) or 2A.2(b), in
which case such Research Costs will be reimbursed in accordance with Section 2A.3; 
 (k) Achillion shall be solely
responsible for the US$[**] IND filing milestone payment due to Chiron Corporation pursuant to Section 3.1.7(a) of the License Agreement dated [**] by and between Chiron Corporation and Gilead (the “Chiron License”) (or, if
such milestone payment amount is reduced pursuant to any applicable provision of the Chiron License, the reduced milestone payment amount), if such milestone payment becomes due based on Achillion’s research and Development activities with
respect to ACH-1095 during the Interim Period; and 
 (l) except as provided in this Section 2A, all provisions of the
Agreement shall remain in effect with respect to the Other Compounds during the Interim Period. 
 2A.2 Opt-In
Right. 
 (a) Achillion shall promptly notify Gilead in writing of the outcome of the FDA Meeting, and
contemporaneously shall provide Gilead with copies of all material correspondence sent to and received from the FDA pertaining to such FDA Meeting to the extent not already provided pursuant to Section 2A.1(e) above (such notice and
correspondence, collectively the “FDA Meeting Notice”). Gilead may exercise its right to fully participate in the Development and commercialization of ACH-1095 and to continue the Development and commercialization of the Other
Compounds, and Licensed Products containing any of the Compounds, by delivering written notice of such exercise to Achillion within thirty (30) days after Gilead’s receipt of the complete FDA Meeting Notice. 
  

 3 

 (b) Achillion shall promptly notify Gilead upon establishment of Proof of Concept for
ACH-1095, which notice shall include (i) a full disclosure of all materially relevant data as described in Exhibit 1.3 and Exhibit 2.2, and (ii) a reasonable estimate of the Research Costs that Gilead would be required to reimburse in
accordance with Section 2A.3 below (such notice, data and cost estimate, collectively the “POC Notice”). Gilead may exercise its right to fully participate in the Development and commercialization of ACH-1095 and to continue
the Development and commercialization of the Other Compounds, and Licensed Products containing any of the Compounds, by delivering written notice of such exercise to Achillion within forty five (45) days after Gilead’s receipt of the
complete POC Notice. 
 (c) Achillion shall promptly notify Gilead upon Achillion’s failure to establish Proof of Concept
after Achillion conducts a phase 1b proof-of-concept study in HCV-infected patients, which notice shall include (i) a full disclosure of all materially relevant data generated in the course of Achillion’s research and Development
Activities during the Interim Period, and (ii) a reasonable estimate of the Research Costs that Gilead would be required to reimburse in accordance with Section 2A.3 below (such notice, data and cost estimate, collectively the “POC
Failure Notice”). Gilead may exercise its right to fully participate in the Development and commercialization of ACH-1095 and to continue the Development and commercialization of the Other Compounds, and Licensed Products containing any of the
Compounds, by delivering written notice of such exercise to Achillion within forty five (45) days after Gilead’s receipt of the complete POC Failure Notice. 
 (d) Except as expressly set forth in Sections 2A.1, 2A.2(a), 2A.2(b) and 2A.2(c), Gilead shall have no other right to participate in the Development and commercialization of ACH-1095, or any Licensed
Products containing ACH-1095, during the Interim Period. 
 2A.3 Effects of Opt-In. 
 (a) Following Achillion’s receipt of Gilead’s notice of exercise of its opt-in right pursuant to Section 2A.2(a), 2A.2(b) or
2A.2(c) (the date of such receipt, the “Opt-In Date”), the Agreement shall apply in full, subject to the following: (i) the Parties shall again bear all Research Costs incurred thereafter in accordance with
Section 2.4(c); (ii) all rights and obligations described as applying upon or after the “establishment of Proof of Concept” (or words of similar effect) shall apply upon or after the later of (A) the Opt-In Date or
(B) the establishment of Proof of Concept; and (iii) notwithstanding Section 3.1(a), if the Opt-In Date occurs after the establishment of Proof of Concept, the Development Committee shall be established within ten (10) days after
the Opt-In Date. 
 (b) If Gilead exercises its opt-in right pursuant to Section 2A.2(b) or 2A.2(c), Achillion shall
provide Gilead with an invoice for (i) all Research Costs with respect to conducting research and Development activities with respect to ACH-1095 directed to establishing Proof of Concept pursuant to clause (b) of the “Research
Costs” definition and incurred by Achillion between the Amendment #3 Effective Date and the Opt-In Date (for which purpose all of Achillion’s reasonable and actual out-of-pocket costs for activities with respect to

  

 4 

 
the clinical Development of ACH-1095 shall be deemed to have been approved in advance by the Research Committee, to have been reflected in, and consistent with, the Research Plan and the Budget
and to be activities required for obtaining Proof of Concept, for purposes of the “External Research Costs” and “Research Costs” definitions) and (ii) any amount paid by Achillion to Chiron Corporation pursuant to
Section 2A.1(k). Gilead shall pay the invoiced amount to Achillion within sixty (60) calendar days after Gilead’s receipt of such invoice. 
 2A.4 Failure to Opt-In. If Achillion provides a POC Notice under Section 2A.2(b) or a POC Failure Notice under Section 2A.2(c) and Gilead does not exercise its opt-in
right pursuant to Section 2A.2(a), 2A.2(b) or 2A.2(c) on or before the expiration of the Interim Period, then ACH-1095 shall cease to be a Compound (and shall cease to be the Lead Compound) under this Agreement, and, with respect to ACH-1095,
this Agreement shall be deemed to have been terminated by Gilead in accordance with Section 10.2. The Parties shall discuss whether any Other Compound shall be designated as the Lead Compound, and Gilead will have the sole discretion whether to
make any such designation. If Gilead elects to make such designation, then this Agreement shall remain in force with respect to the Other Compounds; provided that, (a) concurrently with such designation, Gilead shall provide to
Achillion a reasonable plan for the Development of such Lead Compound, (b) thereafter Gilead shall commence preclinical Development of such Lead Compound within one hundred twenty (120) days after such designation and use Commercially
Diligent Efforts to Develop, commercialize and market at least one Licensed Product in the HCV Field in each Major Market, and (c) the Parties shall again bear all Research Costs incurred thereafter in accordance with Section 2.4(c) with
respect to such Lead Compound. If no such designation is made prior to the expiration of the Interim Period, then the Agreement shall be deemed to have been terminated in its entirety by Gilead in accordance with Section 10.2, effective upon
the expiration of the Interim Period, with the effects described in Section 10.4(a), 10.4(d) and 10.5.” 
 6.
Amendment of Section 10.2. Section 10.2 of the Agreement is hereby restated in its entirety to read as follows: 
 “Elective Termination by Gilead. Gilead shall have the right in its sole discretion and for any reason to terminate this Agreement in its entirety at any time upon thirty (30) days advance
written notice to Achillion.” 
 7. Supply of Existing Quantities of ACH-1095. At any time during the Interim
Period, Achillion shall have the option to request the transfer of Gilead’s existing inventory of ACH-1095 to Achillion. The terms and conditions governing any such transfer and Achillion’s subsequent use of such ACH-1095 shall be the same
as set forth in Section 10.4(b)(vii) of the Agreement with respect to Licensed Product supplied by Gilead thereunder. 
 8.
No Other Amendment. Except as expressly set forth herein, the amendment provided herein shall not, by implication or otherwise, limit, constitute a waiver of, or otherwise affect the rights and remedies of Gilead or Achillion under the
Agreement, nor shall it constitute a waiver of any default, nor shall it alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Agreement. The amendment provided herein shall
apply and be effective only with respect to the provisions of the Agreement specifically referred by this Amendment #3. 
  

 5 

 9. Governing Law. This Amendment #3 shall be governed and construed in accordance
with the laws of the State of New York, except for any of its choice of law rules that would require the application of the laws of another jurisdiction. 
 10. Counterparts. This Amendment #3 may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which shall be one and the same document. 
 [Remainder of Page Intentionally Left Blank] 
  

 6 

 IN WITNESS WHEREOF, the Parties hereto have executed this Amendment #3 as of the date first
above written. 
  

					
	ACHILLION PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Michael D. Kishbauch

		 	Name:	 	Michael D. Kishbauch
		 	Title:	 	President and CEO
	
	GILEAD SCIENCES, INC.
		
	By:	 	 /s/ John F. Milligan

		 	Name:	 	John F. Milligan, Ph.D.
		 	Title:	 	President and COO

  

 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}]]